Kubota Pharmaceutical
Tokyo, Japan· Est.
A Japanese biotech company developing small molecule drugs and devices to treat and cure blinding diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Japanese biotech company developing small molecule drugs and devices to treat and cure blinding diseases.
Ophthalmology
Technology Platform
The company develops small molecule drugs targeting the visual cycle and designs medical devices for vision correction/preservation.
Opportunities
Growth opportunities include expanding the compassionate use program for Emixustat into broader regulatory approvals and leveraging Kubota Glass® to build a commercial foundation in the vision care device market.
Risk Factors
Key risks include clinical failure or regulatory hurdles for Emixustat, commercial execution challenges for Kubota Glass®, and dependence on a narrow pipeline focused on a single therapeutic area.
Competitive Landscape
Competes with other ophthalmology-focused biotechs and device companies (e.g., Genentech/Roche, Novartis, Regeneron for drugs). Differentiation lies in its dual drug-device strategy and mission-driven focus on curing blindness.